By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Nir Barzilai on Metformin, TAME Trial, and Longevity Genetics
- Barzilai explains that the TAME trial aims to give the FDA a path to an aging indication by testing whether metformin delays a cluster of age-related diseases in 3,000 people aged 65 to 80 across 14 US centers.
- He argues metformin's value as an aging drug rests on human data like a large UK cohort showing diabetics on metformin had 17% lower mortality than matched non-diabetics, plus a small biopsy study showing effects beyond metabolism.
- Barzilai describes centenarian research showing the growth hormone/IGF pathway is the most common genomic alteration, with sex differences, protective gene-gene interactions such as CETP VV, and many centenarians carrying supposedly pathogenic mutations without disease.
- The two debate insulin resistance, with Barzilai proposing it may be a protective stress response, and discuss visceral fat removal, fasting, autophagy, and caloric restriction as longevity levers.
- On supplements, Barzilai takes a cautious stance on NAD precursors like NMN, stressing that without controlled clinical trials benefits remain guesswork, and he concedes the field's biggest uncertainty is how animal findings translate to humans.
IDEAS WORTH REMEMBERING
5 ideasTAME is built to establish aging as a treatable indication
Barzilai says the trial uses a composite of age-related diseases because the FDA lacks an aging indication and he wants to show a clustered delay rather than effects on any single disease.
Human data support metformin beyond diabetes
In a UK study, diabetic patients on metformin had 17% less mortality than matched non-diabetic controls, while sulfonylurea users had higher mortality; hundreds of studies also link metformin to fewer cancers, except possibly prostate.
Metformin's mechanism is complex and may be secondary to fixing aging
Barzilai describes effects through AMPK, mTOR, complex I, and epigenetic routes, but suggests many measured changes like lower insulin and inflammation may result from aging being slowed rather than being direct actions.
Centenarians carry a delay in disease, not immunity
Barzilai says they show compression of morbidity, and that many carry mutations that should cause disease yet remained healthy, likely due to protective gene-gene interactions such as CETP VV offsetting an Lp(a) genotype.
Low IGF signaling appears beneficial, especially in women
Barzilai reports that centenarian women with lowest IGF-1 levels lived longer with less cognitive decline, and an IGF receptor antibody extended lifespan in female mice by 10%, though males did not show the same benefit.
WORDS WORTH SAVING
5 quotesI'm not for longevity. I'm just for healthspan, right? So if we can live healthy, healthy, healthy, die, that's fine with me.
— Dr. Nir Barzilai
I call metformin a tool from my perspective. It's just a tool to show that we can target aging, because I think that there'll be much better drugs and combination drugs than other in the future.
— Dr. Nir Barzilai
We have two APOE4 100 years old people that the textbook would say they're demented at 70 and dead at 80, and they're not demented and not dead at 100
— Dr. Nir Barzilai
Unless you do a clinical study, you can remain guessing.
— Dr. Nir Barzilai
We know that it's never too late to target aging, and that's what we're targeting.
— Dr. Nir Barzilai
High quality AI-generated summary created from speaker-labeled transcript.
